Satellos Bioscience Inc. Common Stock (MSLE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Satellos Bioscience Inc. Common Stock (MSLE) has a cash flow conversion efficiency ratio of -0.261x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.26 Million) by net assets ($27.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Satellos Bioscience Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2021–2025)
This chart illustrates how Satellos Bioscience Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Satellos Bioscience Inc. Common Stock total liabilities for a breakdown of total debt and financial obligations.
Satellos Bioscience Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Satellos Bioscience Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Military Insurance Corp
VN:MIG
|
N/A |
|
SMC Global Securities Limited
NSE:SMCGLOBAL
|
-0.168x |
|
Mammoth Energy Services Inc
NASDAQ:TUSK
|
-0.010x |
|
All For One Steeb AG
F:A1OS
|
-0.010x |
|
Horizon Gold Ltd
AU:HRN
|
-0.016x |
|
Dongsung Corporation
KO:102260
|
0.007x |
|
Meghmani Organics Limited
NSE:MOL
|
0.029x |
|
Cypark Resources Berhad
KLSE:5184
|
-0.001x |
Annual Cash Flow Conversion Efficiency for Satellos Bioscience Inc. Common Stock (2021–2025)
The table below shows the annual cash flow conversion efficiency of Satellos Bioscience Inc. Common Stock from 2021 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Satellos Bioscience Inc. Common Stock worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $27.78 Million | $-23.60 Million | -0.849x | -130.76% |
| 2024-12-31 | $47.28 Million | $-17.40 Million | -0.368x | -29.21% |
| 2023-12-31 | $30.66 Million | $-8.73 Million | -0.285x | +83.41% |
| 2022-12-31 | $2.48 Million | $-4.26 Million | -1.717x | -257.45% |
| 2021-12-31 | $8.22 Million | $-3.95 Million | -0.480x | -- |
About Satellos Bioscience Inc. Common Stock
Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company uses its proprietary discovery platform MyoReGenX, an automated microscopy system that recapitulates the muscle stem cell environment ex-vivo. It develops SAT-3247, an oral, small m… Read more